For comparing the primary end point (day 3 24-h glucose level) between groups, a linear mixed model was applied, incorporating repeated measurements for each patient, with treatment group as the main fixed effect and patients as the random effect.
We compared end points for the IC and IS groups in three patterns: (1) comparison using all the patients in the cohort (n = 76), (2) comparison among cN0 1 patients (n = 52), and (3) comparison of a selected cohort in which IC patients were individually matched with IS patients by PS in all the patients (n = 32), and cN0 1 patients (n = 24).
Average and spread are reported as mean ± SD or median [25th - 75th perc.] with paired t-test or Wilcoxon's test applied as appropriate for comparing baseline to protocol end.
We argue that pathway-centric analyses via the MetaPathways pipeline and Pathway Tools provides the scientific user community with an end-to-end solution for comparing ePGDBs constructed from environmental sequence information revealing known and novel network properties.
For these analyses, we compared end-of-life care between patients with cancer in the four countries, with Belgium as the reference category, and adjusted differences in place of death, age, gender and the types of malignancy.
For these analyses, we compared end-of-life care between patients with cancer in the four countries, with Belgium as the reference category, and adjusted differences in place of death, age, gender, types of malignancy and the number of GPs contact in the last week of life.
The paired t test was used for comparing percentage change of variables, end values, and baseline values.
FSIQ was chosen as the end point for comparing risk factors, but this might not be the outcome that captures the most important impact of a risk factor.
These data are highly relevant for comparing decentralised treatment options with existing end-of-pipe treatments, for feeding into risk assessments and for design purposes.
Five of our putative novel miRNA loci had ten or more reads, and for these we compared the end variation to the miRNA and non-miRNA distributions.
